35 High pathologic complete remission rate with liposome-encapsulated doxorubicin + paclitaxel + trastuzumab as primary treatment in HER-2 positive operable breast cancer: clinical experience

Authors :: Angel Guerrero-Zotano
M.I. Tortajada
V. Guillem
S. Blanch
J. Camp
A. Ruiz
Miguel Angel Climent
P. Vidal
F. Gozalbo
Joaquín Gavilá
Source :: European Journal of Cancer Supplements. 8:68-69
Publication Year :: 2010
Publisher :: Elsevier BV, 2010.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Paclitaxel/trastuzumab
business.industry
Liposome-encapsulated doxorubicin
medicine.disease
Breast cancer
Internal medicine
medicine
Primary treatment
business
Pathologic Complete Remission

Full Text Access

Tools